Skip to main navigation Skip to search Skip to main content

Europe should lead in coordinated procurement of quality-assured medicines for programmes in low-income and middle-income countries

    Research output: Contribution to journalA1: Peer-reviewed journal articlespeer-review

    46 Downloads (Pure)

    Abstract

    Europe should lead in coordinated procurement of quality-assured medicines for programmThoughtful procurement policies in humanitarian and development medical programmes can mitigate the risk of purchasing poor-quality medicines, allowing to address fundamental moral obligation to equity, transparency and accountability. European donors are aware of the quality problems in the global pharmaceutical market, and some are already translating awareness into explicit procurement and quality assurance policies. However, a joint position and coordinated action is lacking.
    European donors should share existing knowledge and tools, seek the input of recipient countries, and develop a joint position on how the donor community
    can help to ensure access to affordable and quality-assured health products—also during public health emergencies such as the COVID-19 pandemic.
    Applying stringent and harmonised quality assurance requirements, European donors and their implementing organisations can help shaping the global pharmaceutical market towards affordable, quality assured products.es in low-income and middle-income countries
    Original languageEnglish
    Article numbere003283
    JournalBMJ Global Health
    Volume5
    Issue number7
    Number of pages5
    ISSN2059-7908
    DOIs
    Publication statusPublished - 2020

    Keywords

    • Developing Countries
    • Europe
    • Health Services Accessibility
    • Humans
    • Income
    • Poverty

    Fingerprint

    Dive into the research topics of 'Europe should lead in coordinated procurement of quality-assured medicines for programmes in low-income and middle-income countries'. Together they form a unique fingerprint.

    Cite this